Formulation and characterization of tenofovir disproxyl fumerate nanoparticles prepared by nanoprecipitation method

Tenofovir disproxyl fumerate (TDF) is widely used drug in anti HIV treatment. The main disadvantage with TDF is its low bioavailability. To overcome this problem TDF is formulated in to nanoparticles by using nanoprecipitation method. The formulated nanoparticles were in the range of 106.8nm to 516.4nm. The effect of PLGA and TPGS on the formulated nanoparticles were also studied. It is evident that the concentration of PLGA played an important role in the entrapment and drug loading capacity. On the basis of drug loaded and entrapment efficiency the F8 formulation was considered as optimized formulation. Different analytical techniques were used to determine the amount of drug present in the optimized formulation. The optimized formulation (F8) was subjected to different drug release kinetic models and its stability studies were also conducted in accordance with ICH guidelines.